6LEL image
Entry Detail
PDB ID:
6LEL
Keywords:
Title:
Structure of E. coli beta-glucuronidase complex with C6-hexyl uronic isofagomine
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2019-11-25
Release Date:
2021-01-27
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.28
R-Value Work:
0.23
R-Value Observed:
0.24
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Beta-D-glucuronidase
Chain IDs:A, B
Chain Length:604
Number of Molecules:2
Biological Source:Escherichia coli
Ligand Molecules
Primary Citation
Entropy-driven binding of gut bacterial beta-glucuronidase inhibitors ameliorates irinotecan-induced toxicity.
Commun Biol 4 280 280 (2021)
PMID: 33664385 DOI: 10.1038/s42003-021-01815-w

Abstact

Irinotecan inhibits cell proliferation and thus is used for the primary treatment of colorectal cancer. Metabolism of irinotecan involves incorporation of β-glucuronic acid to facilitate excretion. During transit of the glucuronidated product through the gastrointestinal tract, an induced upregulation of gut microbial β-glucuronidase (GUS) activity may cause severe diarrhea and thus force many patients to stop treatment. We herein report the development of uronic isofagomine (UIFG) derivatives that act as general, potent inhibitors of bacterial GUSs, especially those of Escherichia coli and Clostridium perfringens. The best inhibitor, C6-nonyl UIFG, is 23,300-fold more selective for E. coli GUS than for human GUS (Ki = 0.0045 and 105 μM, respectively). Structural evidence indicated that the loss of coordinated water molecules, with the consequent increase in entropy, contributes to the high affinity and selectivity for bacterial GUSs. The inhibitors also effectively reduced irinotecan-induced diarrhea in mice without damaging intestinal epithelial cells.

Legend

Protein

Chemical

Disease

Primary Citation of related structures